Bruce Stroever - 04 Jun 2025 Form 4 Insider Report for Bone Biologics Corp (BBLG)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
06 Jun 2025, 17:01:18 UTC
Prior SEC filing
19 Sep 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Bruce Stroever

Key filing fact

Bruce Stroever filed Form 4 for Bone Biologics Corp (BBLG) on 06 Jun 2025.

Key facts

  • This page summarizes Bruce Stroever's Form 4 filing for Bone Biologics Corp (BBLG).
  • 1 reported transaction and 6 derivative rows are listed below.
  • Accepted by SEC: 06 Jun 2025, 17:01.

Change

  • Previous filing in this sequence was filed on 19 Sep 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001657728 Primary reporting owner

Stroever Bruce

Relationship
Director
Address
C/O BONE BIOLOGICS CORP,, 2 BURLINGTON WOODS DR.SUITE 100, BURLINGTON,
Signature
/s/ Bruce Stroever
Signature date
06 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BBLG transaction Derivative

Non-Employee Stock Option

Award

Transaction value
$0
Shares
+62,894
Change %
Price
$0.000000
Shares after
62,894
Date
04 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
62,894
Exercise price
$0.8800
Footnotes
F1
BBLG holding Derivative

Non-Employee Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
30,713
Date
04 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
30,713
Exercise price
$1.73
Footnotes
F2
BBLG holding Derivative

Non-Employee Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
10,721
Date
04 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
10,721
Exercise price
$5.12
Footnotes
F3
BBLG holding Derivative

Non-Employee Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
154
Date
04 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
154
Exercise price
$387.28
Footnotes
F3
BBLG holding Derivative

Non-Employee Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
37
Date
04 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
37
Exercise price
$844.80
Footnotes
F3
BBLG holding Derivative

Non-Employee Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
13
Date
04 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
13
Exercise price
$1260.00
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests in four equal quarterly installments.

Footnote F2

This option was granted on 9/17/2024 and vests in four equal quarterly installments.

Footnote F3

This option is fully exercisable as of the date of this report.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .